After a no-good, very bad year, Axovant reshuffles the deck
Bad news has piled up at Axovant, including the poor showing of its Parkinsons/Lewy body drug, and now the CEO David Hung is out after a mere 10 months on the job.
Bad news has piled up at Axovant, including the poor showing of its Parkinsons/Lewy body drug, and now the CEO David Hung is out after a mere 10 months on the job.
Axovant founder and CEO Vivek Ramaswamy has stepped back from the top job, passing the reins to David Hung as the company nears a Phase 3 data readout for its lead Alzheimer's drug candidate.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.